EGF receptor as a drug target in arterial hypertension

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 526-538

  Bełtowski, Jerzy ^a   Lowicka E ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Arterial hypertension; Epidermal growth factor receptor; Extracellular signal regulated kinases; Leptin; Metabolic syndrome; Receptor transactivation; Receptor tyrosine kinase inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANTISENSE OLIGODEOXYNUCLEOTIDE; BOSENTAN; CALCIUM ANTAGONIST; CANERTINIB; CATECHOLAMINE DERIVATIVE; CETUXIMAB; DIPHTHERIA TOXOID CRM197; DOXYCYCLINE; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GW 2974; ILOMASTAT; LAPATINIB; MATRIX METALLOPROTEINASE INHIBITOR; PANITUMUMAB; SPIRONOLACTONE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ANTIHYPERTENSIVE AGENT; LIGAND;

ADVANCED CANCER; ALLERGIC REACTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; FLUID RETENTION; HUMAN; HYPERTENSION; KIDNEY PERFUSION; KIDNEY TUBULE ABSORPTION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; METASTASIS; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; RASH; REGULATORY MECHANISM; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; ANIMAL; ARTERY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; TRANSCRIPTION INITIATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; HUMANS; HYPERTENSION; LIGANDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 67649892045     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788167619     Document Type: Article

References (126)

1. Dreux, A.C.; Lamb, D.J.; Modjtahedi, H.; Ferns, G.A. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis, 2006, 186, 38-53.
2. Chan, H.W.; Smith, N.J.; Hannan, R.D.; Thomas, W.G. Tackling the EGFR in pathological tissue remodelling. Pulm. Pharmacol. Ther., 2006, 19, 74-8.
3. Downey, J.M.; Davis, A.M.; Cohen, M.V. Signaling pathways in ischemic preconditioning. Heart Fail. Rev., 2007, 12, 181-8.
4. Ushiro, H.; Cohen, S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem., 1980, 255, 8363-5.
5. Downward, J.; Yarden, Y.; Mayes, E.; Scrace, G.; Totty, N.; Stockwell, P.; Ullrich, A.; Schlesinger, J.; Waterfield, M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature, 1984, 307, 521-7.
6. Schechter, A.L.; Stern, D.F.; Vaidyanathan, L.; Decker, S.J.; Drebin, J.A.; Greene, M.I.; Weinberg, R.A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 1984, 312, 513-6.
7. Burgess, A.W.; Cho, H.S.; Eigenbrot, C.; Ferguson, K.M.; Garrett, T.P.; Leahy, D.J.; Lemmon, M.A.; Sliwkowski, M.X.; Ward, C.W.; Yokoyama, S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell, 2003, 12, 541-52.
8. Zhang, H.; Berezov, A.; Wang, Q.; Zhang, G.; Drebin, J.; Murali, R.; Greene, M.I. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest., 2007, 117, 2051-8.
9. Lee, S.R.; Kwon, K.S.; Kim, S.R.; Rhee, S.G. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem., 1998, 273, 15366-72.
10. Cohen, S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem., 1962, 237, 1555-62.
11. Gregory, H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature, 1975; 257, 325-7.
12. Nishi, E.; Klagsbrun, M. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors, 2004, 22, 253-60.
13. Berasain, C.; Castillo, J.; Perugorría, M.J.; Prieto, J.; Avila, M.A. Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett., 2007, 254, 30-41.
14. Dunbar, A.J.; Goddard, C. Structure-function and biological role of betacellulin. Int. J. Biochem. Cell Biol., 2000, 32, 805-15.
15. Garratt, A.N. "To erb-B or not to erb-B..." Neuregulin-1/ErbB signaling in heart development and function. J. Mol. Cell. Cardiol., 2006, 41, 215-8.
16. Breuleux, M. Role of heregulin in human cancer. Cel.l Mol. Life Sci., 2007, 64, 2358-77.
17. Ohtsu, H.; Dempsey, P.J.; Eguchi, S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell. Physiol., 2006, 291, C1-10.
18. Daub, H.; Weiss, F.U.; Wallasch, C.; Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature, 1996, 379, 557-60.
19. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature, 1999, 402, 884-8.
20. Biscardi, J.S.; Maa, M.C.; Tice, D.A.; Cox, M.E.; Leu, T.H., Parsons, S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem., 1999, 274, 8335-43.
21. Yamauchi, T.; Ueki, K.; Tobe, K.; Tamemoto, H.; Sekine, N.; Wada, M.; Honjo, M.; Takahashi, M.; Takahashi, T.; Hirai, H.; Tushima, T.; Akanuma, Y.; Fujita, T.; Komuro, I.; Yazaki, Y.; Kadowaki, T. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature, 1997, 390, 91-6.
22. Frank, G.D.; Mifune, M.; Inagami, T.; Ohba, M.; Sasaki, T.; Higashiyama, S.; Dempsey, P.J.; Eguchi, S. Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: role of metalloprotease and protein kinase C-delta. Mol. Cell. Biol.,2003, 23, 1581-9.
23. Eguchi, S.; Numaguchi, K.; Iwasaki, H.; Matsumoto, T.; Yamakawa, T.; Utsunomiya, H.; Motley, E.D.; Kawakatsu, H.; Owada, K.M.; Hirata, Y.; Marumo, F.; Inagami, T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J. Biol. Chem., 1998, 273, 8890-6.
24. Eguchi, S.; Iwasaki, H.; Hirata, Y.; Frank, G.D.; Motley, E.D.; Yamakawa, T.; Numaguchi, K.; Inagami, T. Epidermal growth factor receptor is indispensable for c-Fos expression and protein synthesis by angiotensin II. Eur. J. Pharmacol., 1999, 376, 203-6.
25. Eguchi, S.; Iwasaki, H.; Inagami, T.; Numaguchi, K.; Yamakawa, T.; Motley, E.D.; Owada, K.M.; Marumo, F.; Hirata, Y. Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells. Hypertension, 1999, 33, 201-6.
26. Bokemeyer, D.; Schmitz, U.; Kramer, H.J. Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int., 2000, 58, 549-58.
27. Eguchi, S.; Dempsey, P.J.; Frank, G.D.; Motley, E.D.; Inagami, T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J. Biol. Chem., 2001, 276, 7957-62.
28. Ushio-Fukai, M.; Griendling, K.K.; Becker, P.L.; Hilenski, L.; Halleran, S.; Alexander, R.W. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 489-95.
29. Saito, S.; Frank, G.D.; Motley, E.D.; Dempsey, P.J.; Utsunomiya, H.; Inagami, T.; Eguchi, S. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem. Biophys. Res. Commun., 2002, 294, 1023-9.
30. Seta, K.; Sadoshima J. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced transactivation of the epidermal growth factor receptor. J. Biol. Chem., 2003, 278, 9019-26.
31. Miura, S.; Zhang, J.; Matsuo, Y.; Saku, K.; Karnik, S.S. Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens. Res., 2004, 27, 765-70.
32. Fujiyama, S.; Matsubara, H.; Nozawa, Y.; Maruyama, K.; Mori, Y.; Tsutsumi, Y.; Masaki, H.; Uchiyama, Y.; Koyama, Y.; Nose, A.; Iba, O.; Tateishi, E.; Ogata, N.; Jyo, N.; Higashiyama, S. Iwasaka, T. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ. Res., 2001, 88, 22-9.
33. Zhang, H.; Chalothorn, D.; Jackson, L.F.; Lee, D.C.; Faber, J.E. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ. Res., 2004, 95, 989-97.
34. Hao, L.; Du, M.; Lopez-Campistrous, A.; Fernandez-Patron, C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res., 2004, 94, 68-76.
35. Iwasaki, H.; Eguchi, S.; Marumo, F.; Hirata, Y. Endothelin-1 stimulates DNA synthesis of vascular smooth-muscle cells through transactivation of epidermal growth factor receptor. J. Cardiovasc. Pharmacol., 1998, 31, S182-4.
36. Iwasaki, H.; Eguchi, S.; Ueno, H.; Marumo, F.; Hirata, Y. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology, 1999, 140, 4659-68.
37. Kawanabe, Y.; Hashimoto, N.; Masaki, T. Characterization of Ca2+ channels involved in ET-1-induced transactivation of EGF receptors. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H2671-5.
38. Flamant, M.; Tharaux, P.L.; Placier, S.; Henrion, D.; Coffman, T.; Chatziantoniou, C, Dussaule, J.C. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J., 2003, 17, 327-9.
39. Kawanabe, Y.; Nozaki, K.; Hashimoto, N.; Masaki, T. Involvement of extracellular Ca2+ influx and epidermal growth factor receptor tyrosine kinase transactivation in endothelin-1-induced arachidonic acid release. Br. J. Pharmacol., 2003, 139, 1516-22.
40. Young, M.J. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr. Opin. Nephrol. Hypertens., 2008, 17, 174-80.
41. Grossmann, C.; Gekle, M. Non-classical actions of the mineralo-corticoid receptor: misuse of EGF receptors? Mol. Cell. Endocrinol., 2007, 277, 6-12.
42. Krug, A.W.; Grossmann, C.; Schuster, C.; Freudinger, R.; Mildenberger, S.; Govindan, M.V.; Gekle, M. Aldosterone stimulates epidermal growth factor receptor expression. J. Biol. Chem., 2003, 278, 43060-6.
43. Grossmann, C.; Krug, A.W.; Freudinger, R.; Mildenberger, S.; Voelker, K.; Gekle, M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab., 2007, 292, E1790-800.
44. Mazak, I.; Fiebeler, A.; Muller, D.N.; Park, J.K.; Shagdarsuren, E.; Lindschau, C.; Dechend, R.; Viedt, C.; Pilz, B.; Haller, H.; Luft, F.C. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation, 2004, 109, 2792-800.
45. Min, L.J.; Mogi, M.; Li, J.M.; Iwanami, J.; Iwai, M.; Horiuchi, M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res., 2005, 97, 434-42.
46. Sumi, S.; Inoue, K.; Hosotani, R.; Kogire, M.; Doi, R.; Yun, M.; Higashide, S.; Minote, H.; Takaori, K.; Kaji, H. Effect of human epidermal growth factor (hEGF) on splanchnic circulation in dogs. Life Sci., 1990, 47, 1115-9.
47. Gan, B.S.; MacCannell, K.L.; Hollenberg, M.D. Epidermal growth factor-urogastrone causes vasodilatation in the anesthetized dog. J. Clin. Invest., 1987, 80, 199-206.
48. Keiser, J.A.; Ryan, M.J. Hemodynamic effects of epidermal growth factor in conscious rats and monkeys. Proc. Natl. Acad. Sci. U S A, 1996, 93, 4957-61.
49. Gan, B.S.; Bolt, G.R.; Hollenberg, M.D.; MacCannell, K.L. Species variation in the vascular effects of epidermal growth factor-urogastrone. Proc. West. Pharmacol. Soc., 1986, 29, 483-4.
50. Berk, B.C.; Brock, T.A.; Webb, R.C.; Taubman, M.B.; Atkinson, W.J.; Gimbrone, M.A.; Alexander, R.W. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J. Clin. Invest., 1985, 75, 1083-6.
51. Rippetoe, P.E.; Olson, J.W.; Altiere, R.J.; Pauly, T.H.; Gillespie, M.N. Epidermal growth factor augments reactivity to angiotensin II in the rat pulmonary circulation. Am. Rev. Respir. Dis., 1989, 140, 821-4.
52. Merkel, L.A.; Rivera, L.M.; Colussi, D.J.; Perrone, M.H. Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem. Biophys. Res. Commun., 1993, 192, 1319-26.
53. deBlois, D.; Drapeau, G.; Petitclerc, E.; Marceau, F. Synergism between the contractile effect of epidermal growth factor and that of des-Arg9-bradykinin or of alpha-thrombin in rabbit aortic rings. Br. J. Pharmacol., 1992, 105, 959-67.
54. Hao, L.; Nishimura, T.; Wo, H.; Fernandez-Patron, C. Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 819-25.
55. Chansel, D.; Ciroldi, M.; Vandermeersch, S.; Jackson, L.F.; Gomez, A.M.; Henrion, D.; Lee, D.C.; Coffman, T.M.; Richard, S.; Dussaule, J.C.; Tharaux P.L. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J., 2006, 20, 1936-8.
56. Kawanabe, Y.; Masaki, T.; Hashimoto, N. Involvement of epidermal growth factor receptor-protein tyrosine kinase transactivation in endothelin-1-induced vascular contraction. J. Neurosurg., 2004, 100, 1066-71.
57. Carmines, P.K.; Fallet, R.W.; Che, Q.; Fujiwara, K. Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. Hypertension, 2001, 37, 569-73.
58. Escano, C.S.; Keever, L.B.; Gutweiler, A.A.; Andresen, B.T. Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blond pressure regulation. J. Pharmacol. Exp. Ther., 2008, 324, 34-42.
59. Lucchesi, P.A.; Sabri, A.; Belmadani, S.; Matrougui, K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation, 2004, 110, 3587-93.
60. Salido, E.; Barajas, L.; Lechago, J.; Laborde, N.; Fisher, D. Immunocytochemical localization of epidermal growth factor in mouse kidney. J. Histochem. Cytochem., 1986, 34, 1155-60.
61. Salido, E.C.; Yen, P.H.; Shapiro, L.J.; Fisher, D.A.; Barajas, L. In situ hybridization of prepro-epidermal growth factor mRNA in the mouse kidney. Am. J. Physiol., 1989, 256, F632-8.
62. Skov Olsen, P.; Nexø, E.; Poulsen, S.S.; Hansen, H.F.; Kirkegaard, P. Renal origin of rat urinary epidermal growth factor. Regul. Pept., 1984, 10, 37-45.
63. Breyer, M.D.; Redha, R.; Breyer, J.A. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am. J. Physiol., 1990, 259, F553-8.
64. Liu, J.Y.; Lei, W.H.; Brody, A.R.; Hoyle, G.W. Investigation of tissue preparation conditions for non-radioactive in situ hybridization: localization of transforming growth factor-alpha message in rat kidney. Histochem. J., 1998, 30, 793-8.
65. Harris, R.C.; Hoover, R.L.; Jacobson, H.R.; Badr, K.F. Evidence for glomerular actions of epidermal growth factor in the rat. J. Clin. Invest., 1988, 82, 1028-39.
66. Gow, C.B.; Phillips, P.A.; Chandler, K.D.; Moore, G.P. Hormonal, fluid, and electrolyte responses of sheep during chronic intravenous infusion of epidermal growth factor. Am. J. Physiol., 1993, 265, R203-10.
67. Gow, C.B.; Grant, S.L.; Phillips, P.A. Effects of indomethacin on epidermal growth factor-induced renal responses in sheep. Clin. Exp. Pharmacol. Physiol., 1997, 24, 680-5.
68. Vehaskari, V.M.; Hering-Smith, K.S.; Moskowitz, D.W.; Weiner, I.D.; Hamm, L.L. Effect of epidermal growth factor on sodium transport in the cortical collecting tubule. Am. J. Physiol., 1989, 256, F803-9.
69. Muto, S.; Furuya, H.; Tabei, K.; Asano, Y. Site and mechanism of action of epidermal growth factor in rabbit cortical collecting duct. Am. J. Physiol., 1991, 260, F163-9.
70. Shen, J.P.; Cotton, C.U. Epidermal growth factor inhibits amiloride-sensitive sodium absorption in renal collecting duct cells. Am. J. Physiol. Renal. Physiol., 2003, 284, F57-64.
71. Tong, Q.; Stockand, J.D. Receptor tyrosine kinases mediate epithelial Na(+) channel inhibition by epidermal growth factor. Am. J. Physiol. Renal. Physiol., 2005, 288, F150-61.
72. Quigley, R.; Baum, M. Effects of epidermal growth factor and transforming growth factor-alpha on rabbit proximal tubule solute transport. Am. J. Physiol., 1994, 266, F459-65.
73. Goodyer, P.R.; Kachra, Z.; Bell, C.; Rozen, R. Renal tubular cells are potential targets for epidermal growth factor. Am. J. Physiol., 1988, 255, F1191-6.
74. Ruiz, O.S.; Qiu, Y.Y.; Cardoso, L.R.; Arruda, J.A. Regulation of the renal Na-HCO3 cotransporter: IX. Modulation by insulin, epidermal growth factor and carbachol. Regul. Pept., 1998, 77, 155-61.
75. Gekle, M.; Freudinger, R.; Mildenberger, S.; Silbernagl, S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am. J. Physiol. Renal. Physiol., 2002, 282, F669-79.
76. Gekle, M.; Freudinger, R.; Mildenberger, S.; Silbernagl, S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids, 2002, 67, 499-504.
77. Féraille, E.; Doucet, A. Sodium-potassium-adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control. Physiol. Rev., 2001, 81, 345-418.
78. Féraille, E.; Carranza, M.L.; Rousselot, M.; Favre, H. Modulation of Na+,K(+)-ATPase activity by a tyrosine phosphorylation process in rat proximal convoluted tubule. J. Physiol., 1997, 498, 99-108.
79. Bełtowski, J.; Wójcicka, G.; Trzeciak, J.; Marciniak, A. H2O2 and Src-dependent transactivation of the EGF receptor mediates the stimulatory effect of leptin on renal ERK and Na+, K+-ATPase. Peptides, 2006, 27, 3234-44.
80. Cui, X.L.; Ding, Y.; Alexander, L.D.; Bao, C.; Al-Khalili, O.K.; Simonson, M.; Eaton, D.C.; Douglas, J.G. Oxidative signaling in renal epithelium: Critical role of cytosolic phospholipase A2 and p38(SAPK). Free Radic. Biol. Med., 2006, 41, 213-21.
81. Chen, J.; Chen, J.K.; Neilson, E.G.; Harris, R.C. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J. Am. Soc. Nephrol., 2006, 17, 1615-23.
82. Alexander, L.D.; Ding, Y.; Alagarsamy, S.; Cui, X.L.; Douglas, J.G. Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor. Kidney Int., 2006, 69, 1823-32.
83. Lee, J.S.; Kim, S.Y.; Kwon, C.H.; Kim, Y.K. EGFR-dependent ERK activation triggers hydrogen peroxide-induced apoptosis in OK renal epithelial cells. Arch. Toxicol., 2006, 80, 337-46.
84. Dong, J.; Ramachandiran, S.; Tikoo, K.; Jia, Z.; Lau, S.S.; Monks, T.J. EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 are required for ROS-induced renal cell death. Am. J. Physiol. Renal Physiol., 2004, 287, F1049-58.
85. Zhuang, S.; Schnellmann, R.G. H2O2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells. Am. J. Physiol. Renal Physiol., 2004, 286, F858-65.
86. Zhuang, S.; Yan, Y.; Han, J.; Schnellmann, R.G. p38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation of renal epithelial cells after oxidant injury. J. Biol. Chem., 2005, 280, 21036-42.
87. Cheng-Hsien, C.; Yung-Ho, H.; Yuh-Mou, S.; Chun-Cheng, H.; Horng-Mo, L.; Huei-Mei, H.; Tso-Hsiao C. Src homology 2-containing phosphotyrosine phosphatase regulates endothelin-1-induced epidermal growth factor receptor transactivation in rat renal tubular cell NRK-52E. Pflugers Arch., 2006, 452, 16-24.
88. Cussac, D.; Schaak, S.; Denis, C.; Paris, H. alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation. J. Biol. Chem., 2002, 277, 19882-8.
89. Garvin, J.L.; Ortiz, P.A. The role of reactive oxygen species in the regulation of tubular function. Acta Physiol. Scand., 2003, 179, 225-32.
90. Markadieu, N.; Crutzen, R.; Blero, D.; Erneux, C.; Beauwens, R. Hydrogen peroxide and epidermal growth factor activate phosphatidylinositol 3-kinase and increase sodium transport in A6 cell monolayers. Am. J. Physiol. Renal. Physiol., 2005; 288, F1201-12.
91. Marciniak, A.; Jamroz-Wiśniewska, A.; Borkowska, E.; Bełtowski, J. Time-dependent effect of leptin on renal Na+,K+-ATPase activity. Acta Biochim. Pol., 2005, 52, 803-9.
92. Jamroz-Wiśniewska, A.; Wójcicka, G.; Łowicka, E.; Ksiazek, M.; Bełtowski, J. Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochem. Pharmacol., 2008, 75, 1623-38.
93. Touyz, R.M.; Wu, X.H.; He, G.; Salomon, S.; Schiffrin, E.L. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension, 2002, 39, 479-85.
94. Florian, J.A.; Dorrance, A.; Webb, R.C.; Watts, S.W. Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281, R878-86.
95. Swaminathan, N.; Sambhi, M.P. Induction of high affinity epidermal growth factor binding in the aorta of Dahl hypertensive rats fed with high salt diet. Hypertens. Res., 1996, 19, 65-8.
96. Ying, W.Z.; Sanders, P.W. Enhanced expression of EGF receptor in a model of salt-sensitive hypertension. Am. J. Physiol. Renal. Physiol., 2005, 289, F314-21.
97. Swaminathan, N.; Vincent, M.; Sassard, J.; Sambhi, M.P. Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta. Clin. Exp. Pharmacol. Physiol., 1996, 23, 793-6.
98. Kim, S.; Zhan, Y.; Izumi, Y.; Yasumoto, H.; Yano, M.; Iwao, H. In vivo activation of rat aortic platelet-derived growth factor and epiderma growth factor receptors by angiotensin II and hypertension. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2539-45.
99. Sambhi, M.P.; Swaminathan, N.; Wang, H.; Rong, H. Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin II. Biochem. Med. Metab. Biol., 1992, 48, 8-18.
100. Lautrette, A.; Li, S.; Alili, R.; Sunnarborg, S.W.; Burtin, M.; Lee, D.C.; Friedlander, G.; Terzi, F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med., 2005, 11, 867-74.
101. Florian, J.A.; Watts, S.W. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am. J. Physiol., 1999, 276, H976-83.
102. Northcott, C.; Florian, J.A.; Dorrance, A.; Watts, S.W. Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension, 2001, 38, 1337-41.
103. Kim, J.; Lee, C.K.; Park, H.J.; Kim, H.J.; So, H.H.; Lee, K.S.; Lee, H.M.; Roh, H.Y.; Choi, W.S.; Park, T.K.; Kim, B. Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats. J. Pharmacol. Sci., 2006, 101, 135-43.
104. Chaldakov, G.N.; Fiore, M.; Tonchev, A.B.; Dimitrov, D.; Pancheva, R.; Rancic, G.; Aloe, L. Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight. Curr. Pharm. Des., 2007, 13, 2176-9.
105. Kralisch, S.; Bluher, M.; Paschke, R.; Stumvoll, M.; Fasshaner, M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev. Med. Chem., 2007, 7, 39-45.
106. Bełtowski, J. Role of leptin in blood pressure regulation and arterial hypertension. J. Hypertens., 2006, 24, 789-801.
107. Bełtowski, J.; Wójcicka, G.; Marciniak, A.; Jamroz, A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci., 2004, 74, 2987-3000.
108. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med., 2008, 358, 1160-74.
109. Lafky, J.M.; Wilken, J.A.; Baron, A.T.; Maile, N.J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta, 2008, 1785, 232-65.
110. Levitzki, A.; Mishani, E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem., 2006, 75, 93-109.
111. Fabian, M.A.; Biggs, W.H. 3rd; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lélias, J.M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockhart, D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol., 2005, 23, 329-36.
112. Fuller, S.J., Sivarajah, K.; Sugden, P.H. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J. Mol. Cell. Cardiol., 2008, 44, 831-54.
113. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc. Natl. Acad. Sci. U S A., 2007, 104, 10607-12.
114. Kagiyama, S.; Eguchi, S.; Frank, G.D.; Inagami, T.; Zhang, Y.C.; Phillips, M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation, 2002, 106, 909-12.
115. Kagiyama, S.; Qian, K.; Kagiyama, T.; Phillips, M.I. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension, 2003, 41, 824-9.
116. François, H.; Placier, S.; Flamant, M.; Tharaux, P.L.; Chansel, D.; Dussaule, J.C.; Chatziantoniou C. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J., 2004, 18, 926-8.
117. Asakura, M.; Kitakaze, M.; Takashima, S.; Liao, Y.; Ishikura, F.; Yoshinaka, T.; Ohmoto, H.; Node, K.; Yoshino, K.; Ishiguro, H.; Asanuna, H.; Sanada, S.; Matsumura, Y.; Takeda, H.; Beppu, S.; Tada, M.; Hori, M.; Higashiyama, S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med., 2002, 8, 35-40.
118. Garofalo, C.; Surmacz, E. Leptin and cancer. J. Cell. Physiol., 2006, 207, 12-22.
119. Shida, D.; Kitayama, J.; Mori, K.; Watanabe, T.; Nagawa, H. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res., 2005, 65, 9159-63.
120. Ogunwobi, O.; Mutungi, G.; Beales, I.L. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology, 2006, 147, 4505-16.
121. Nakano, S.; Kobayashi, N.; Yoshida, K.; Ohno, T.; Matsuoka, H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/ extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens. Res., 2005, 28, 925-36.
122. Fujino, T.; Hasebe, N.; Fujita, M.; Takeuchi, K.; Kawabe, J.; Tobise, K.; Higashiyama, S.; Tanigushi, N.; Kikuchi, K. Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc. Res., 1998, 38, 365-74.
123. Dorrance, A.M.; Osborn, H.L.; Grekin, R.; Webb, R.C. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281, R944-50.
124. Portik-Dobos, V.; Harris, A.K.; Song, W.; Hutchinson, J.; Johnson, M.H.; Imig, J.D.; Pollock, D.M.; Ergul, A. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 290, R435-41.
125. Muthalif, M.M.; Karzoun, N.A.; Gaber, L.; Khandekar, Z.; Benter, I.F.; Saeed, A.E.; Parmentier, J.H.; Estes, A.; Malik, K.U. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension, 2000, 36, 604-9.
126. Muthalif MM, Benter IF, Khandekar Z, Gaber L, Estes A, Malik S, Parmentier, J.H.; Manne, V.; Malik, K.U. Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension, 2000, 35, 457-63.